James Melotek, MD | Authors


Dr. James Melotek on Cetuximab/Chemotherapy Combinations in Head and Neck Cancer

March 08, 2016

Melotek says the trial's primary endpoint was comparison of efficacy when cetuximab is added to both therapies with historical control, with a secondary endpoint being further investigation of the usefulness of both chemotherapy platforms.